Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Postherpetic Neuralgia (PHN) Market Size Forecast: How Big Could The Market Get By 2030?
The postherpetic neuralgia (phn) market size has experienced robust expansion in recent years. It is projected to increase from $0.77 billion in 2025 to $0.82 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. Historically, this growth can be attributed to several factors, including an escalating incidence of herpes zoster infections, the limited availability of treatment options for neuropathic pain, a prevalent reliance on opioid-based pain management strategies, an expanding elderly population, and the gradual broadening of hospital-based pain management services.
The market size for postherpetic neuralgia (phn) is expected to demonstrate robust expansion in the coming years. It is projected to increase to $1.06 billion in 2030, achieving a compound annual growth rate (CAGR) of 6.5%. This anticipated growth can be attributed to several factors including the creation of targeted neuropathic pain treatments, the increasing uptake of biologic and branded pharmaceutical products, the expansion of online pharmacy distribution channels, a heightened focus on patient-centric pain management strategies, and the proliferation of outpatient and ambulatory care facilities. Prominent trends for the forecast period include the rising incidence of shingles within the aging population, a greater adoption of non-opioid pain management therapies, the increasing utilization of transdermal and topical pain relief solutions, a higher demand for long-term chronic pain management, and enhanced awareness alongside earlier diagnosis of phn.
Get A Free Sample Report With In-Depth Market Insights:
Postherpetic Neuralgia (PHN) Market Growth Drivers: What’s Behind The Acceleration?
The rising occurrence of chronic pain conditions is anticipated to drive the expansion of the postherpetic neuralgia (PHN) market in the future. Chronic pain is defined as discomfort that is ongoing or reoccurring for over three months, frequently extending past the typical recovery period of a sickness or wound, thereby impacting an individual’s everyday activities and overall well-being. The widespread nature of chronic pain conditions stems from the aging demographic, given that elderly individuals are more susceptible to degenerative ailments such as arthritis and neuropathy, which result in enduring pain. Postherpetic neuralgia offers valuable assistance for chronic pain research by presenting a distinct framework for investigating nerve-associated pain processes and assessing prolonged treatment approaches. For example, a January 2024 report from the Office for Health Improvement and Disparities, a government body in the UK, indicated that approximately 18.4% of individuals aged 16 and over stated they had a long-term musculoskeletal (MSK) condition in 2023, which was an increase from 17.6% in 2022. Consequently, the rising occurrence of chronic pain conditions is propelling the development of the postherpetic neuralgia (PHN) market.
Postherpetic Neuralgia (PHN) Market Segment Breakdown: Which Categories Lead On Revenue?
The postherpetic neuralgia (phn) market covered in this report is segmented –
1) By Type: Patches, Drugs, Opioids
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End Users: Hospitals, Clinics, Other End Users
Subsegments:
1) By Patches: Transdermal Drug Delivery Patches, Analgesic Patches
2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs
3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists
Postherpetic Neuralgia (PHN) Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies active in the postherpetic neuralgia (PHN) market are concentrating on securing regulatory clearances to broaden their product offerings, gain a competitive edge, and address the substantial unmet clinical demand for more efficacious and tolerable treatments. Regulatory approvals denote the official permissions granted by governmental health bodies that allow a drug or therapy to be lawfully marketed and utilized for a particular medical condition. For instance, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, obtained final approval from the United States Food and Drug Administration to produce and commercialize once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, designated for the management of postherpetic neuralgia (PHN). These gabapentin tablets are intended for treating PHN, which is a type of neuropathic pain resulting from nerve damage caused by the reactivation of the varicella-zoster virus. For PHN, the typical dosing begins with 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with titration up to a maximum of 1800 mg per day (600 mg three times daily) as required for pain relief.
Postherpetic Neuralgia (PHN) Market Leading Players And Competitive Positioning
Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.
View The Full Postherpetic Neuralgia (PHN) Market Report:
Postherpetic Neuralgia (PHN) Market Geographic Distribution And Regional Opportunities
North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Leave a Reply